Life Science Intermediates Market Consolidation: Who will not survive?

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?

- How will the current trends affect the major market segments?

- Which companies will enter the market and which will not survive? This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies. The report presents:

• Internally developed and acquired technologies, and related capabilities.


• Proprietary technologies and patent litigations.

The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages